Trial participation drops off sharply with distance, and travel cost is one of the most frequently cited reasons people decline or withdraw. Reimbursing it is both permitted and increasingly expected, but it sits next to a genuine ethical constraint, and the way a site handles the logistics usually lags well behind the way it handles the ethics.
The issue is undue influence: an offer large enough that somebody agrees to something they would otherwise refuse, or discounts a risk they would otherwise take seriously. Regulators and IRBs have consistently treated reimbursement of actual travel costs as different in kind from payment for participation, because it restores somebody to where they would have been rather than making them better off for enrolling.
Federal guidance has moved further in this direction over time, recognising that failing to reimburse travel is itself a problem: it restricts trials to participants who can afford to take part, which is both an equity failure and a scientific one.
Four principles do most of the work, and they are what an IRB will look for.
The ethics are usually settled. The logistics are usually a mess, and they fail in a specific way: expecting a participant to pay first and claim it back.
A protocol requiring several visits, each with a night or two away, can put a participant several hundred pounds or dollars out of pocket before a single reimbursement lands. For the participants trials most need to reach, that is a barrier whether or not the money eventually comes back, and it is invisible in your data because it shows up as a decline rather than a complaint.
Three, in ascending order of how well they solve the pay-first problem.
Reimbursement after the fact is the default and the weakest: simplest to administer, hardest on the participant, and it selects for people who can float the cost. Stipends paid at each visit are better, though they need care to stay on the reimbursement side of the line rather than reading as payment for taking part. Direct arrangement, where the site or sponsor books and pays for the room, removes the problem entirely: nothing leaves the participant's account, so nothing has to come back.
Whatever structure you choose, the documentation is the part that has to survive an audit and a monitoring visit, and it is what lets you answer questions about the study later.
No. This is general information about how these questions are commonly approached. Your IRB and sponsor decide what a specific study permits, and their determination is the one that governs.
Reimbursing actual, reasonable travel costs is generally treated as removing a barrier rather than creating an incentive, which is why it is widely permitted. The analysis changes as the amount grows beyond real costs, or if support is contingent on completing the study.
Many studies do, and it removes the pay-first barrier that reimbursement creates. It still needs to be in the approved arrangement and described in the consent form, and it raises the practical question of what happens when a visit is rescheduled.
It depends on the protocol. Where a study requires an escort, or the participant cannot travel alone after a procedure, companion travel is commonly covered. Like everything else here, it belongs in the approved arrangement rather than being decided per participant.